Lexaria Authorizes 1-for-15 Reverse Split to Avoid Nasdaq Delisting
LEXX is trading near its 52-week low of $0.43 (1.2% above the low) on elevated volume (2.9× avg).
Summary
Lexaria Bioscience is executing a 1-for-15 reverse stock split effective August 3, 2026, to regain Nasdaq compliance after its stock fell near its 52-week low of $0.43. The move follows a July 13 10-Q that flagged a going concern warning and delisting risk, with zero revenue and a cash runway only into early 2027. The reverse split is a direct response to the minimum bid price requirement, but it does not address the underlying financial distress. The company's survival hinges on its GLP-1 drug development pipeline, with a human pilot study approved in May. The split will mechanically boost the share price, but the market cap remains around $10.8 million, and the fundamental outlook is unchanged.
At the time of this announcement, LEXX was trading at $0.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.8M. The 52-week trading range was $0.43 to $1.55. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.